Skip to main content
Premium Trial:

Request an Annual Quote

William Blair Downgrades Illumina to Market Perform

NEW YORK (GenomeWeb) – Investment bank William Blair today downgraded Illumina's stock to Market Perform from Outperform, citing the company's position in its current new product adoption cycle after the launch of the NovaSeq sequencing system.

In a note to investors, analyst Amanda Murphy noted that llumina's stock has performed well recently and is approaching its all-time high of $241, which it hit on July 20, 2015 after the launch of the HiSeq X. The stock gained 71 percent in 2017.

Murphy also noted, however, that Illumina is a "product cycle company and thus has seen waves of new product adoption." As such, its stock performance and valuation are driven by acceleration and deceleration in growth of instrument adoption.

"Share price depreciation has typically preceded a decline in instrumentation revenue by a quarter or two," Murphy wrote. "While we may be looking at this too simply, instrumentation comparisons become much more difficult after the second quarter of 2018 — looking at prior launches, typically we have seen a bolus of adoption in the first four to six quarters."

William Blair's analysis suggests that Illumina's stock could hit $250, which is a 7 percent upside from the current price, as the product cycle for the NovaSeq continues to ramp up. Therefore, Murphy noted, investors may be better served by waiting for a deceleration in the cycle as an entry point to buying the stock.

Illumina's shares fell 2 percent to $227.99 in morning trading on the Nasdaq.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.